Anzeige
Mehr »
Login
Sonntag, 20.10.2024 Börsentäglich über 12.000 News von 675 internationalen Medien
Diese Aktie steigt um 225%! Ist ein Kupfer-Engpass im Gange?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0LC32 | ISIN: GG00B1FQG453 | Ticker-Symbol: BV1
Frankfurt
15.10.24
17:30 Uhr
31,000 Euro
0,000
0,00 %
1-Jahres-Chart
BOUSSARD & GAVAUDAN HOLDING LIMITED Chart 1 Jahr
5-Tage-Chart
BOUSSARD & GAVAUDAN HOLDING LIMITED 5-Tage-Chart
RealtimeGeldBriefZeit
26,20030,80019.10.
GlobeNewswire (Europe)
137 Leser
Artikel bewerten:
(0)

Boussard & Gavaudan Holding Limited: Results of Annual General Meeting

Boussard & Gavaudan Holding Limited (the "Company")
a closed-ended investment company incorporated with limited liability under the laws of Guernsey
with registration number 45582

Legal Entity Identifier: 5493002XNM3W9D6DF327

Results of Annual General Meeting

The Company hereby gives notification that at the annual general meeting of the Company held on Wednesday, 25 September, 2024 at 11.30 a.m., all resolutions set out in the notice of meeting were duly passed. The Board would like to thank the shareholders of the Company for their continued support.

The details of all resolutions passed are as follows:

ORDINARY BUSINESS - ORDINARY RESOLUTIONS

1. That the Company's annual report and audited financial statements for the year ended 31 December 2023 be received. (2,093,048 votes cast, all in favour, none against and none withheld)

2. That Mr Erich Bonnet who, being eligible and having offered himself for re-election, be re-appointed as a director of the Company. (2,093,048 votes cast, all in favour, none against and none withheld)

3. That Ms Sylvie Sauton who, being eligible and having offered herself for re-election, be re-appointed as a director of the Company. (2,093,048 votes cast, all in favour, none against and none withheld)

4. That Mr Luke Allen who, being eligible and having offered himself for re-election, be re-appointed as a director of the Company. (2,093,048 votes cast, all in favour, none against and none withheld)

5. That Mr Frédéric Hervouet who, being eligible and having offered himself for re-election, be re-appointed as a director of the Company. (2,093,048 votes cast, all in favour, none against and none withheld)

For further information, please contact:

Boussard & Gavaudan Investment Management, LLP
Emmanuel Gavaudan
+44 20 3751 5389

JTC Fund Solutions (Guernsey) Limited
Secretary
+44 (0) 1481 702400

25 September, 2024
Website: www.bgholdingltd.com

The Company is established as a closed-ended investment company domiciled in Guernsey. The Company has been authorised by the Guernsey Financial Services Commission as an authorised closed-ended investment scheme. The Company is registered with the Dutch Authority for the Financial Markets as a collective investment scheme pursuant to article 2:73 in conjunction with 2:66 of the Dutch Financial Supervision Act (Wet op het financieel toezicht). The shares of the Company (the "Shares") are listed on Euronext Amsterdam. The Shares are also listed on the Official List of the UK Listing Authority and admitted to trading on the London Stock Exchange plc's main market for listed securities.

This is not an offer to sell or a solicitation of any offer to buy any securities in the United States or in any other jurisdiction. This announcement is not intended to and does not constitute, or form part of, any offer or invitation to purchase any securities or the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of the securities referred to in this announcement in any jurisdiction in contravention of applicable law.

Neither the Company nor BG Master Fund ICAV have been, and neither will be, registered under the US Investment Company Act of 1940, as amended (the "Investment Company Act"). In addition the securities referenced in this announcement have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"). Consequently any such securities may not be offered, sold or otherwise transferred within the United States or to, or for the account or benefit of, US persons except in accordance with the Securities Act or an exemption therefrom and under circumstances which will not require the issuer of such securities to register under the Investment Company Act. No public offering of any securities will be made in the United States.

You should always bear in mind that:

  • all investment is subject to risk;
  • results in the past are no guarantee of future results;
  • the investment performance of BGHL may go down as well as up. You may not get back all of your original investment; and
  • if you are in any doubt about the contents of this communication or if you consider making an investment decision, you are advised to seek expert financial advice.

This communication is for information purposes only and the information contained in this communication should not be relied upon as a substitute for financial or other professional advice.

END OF ANNOUNCEMENT


© 2024 GlobeNewswire (Europe)
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.